Company Active LTD

Company profile

Oxford Expression Technologies Limited

Oxford Expression Technologies | World leaders in Baculovirus technology

Supporting the global pharma and biotech industries, and a world-renowned centre of excellence for Baculovirus protein expression.

CRN
05874405
Founded
2006
Age
19

Overview

Legal name
OXFORD EXPRESSION TECHNOLOGIES LIMITED
Region
South East England
Registered address
2 COMMUNICATIONS ROAD
GREENHAM BUSINESS PARK
NEWBURY
BERKSHIRE
UNITED KINGDOM
RG19 6AB
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Oxford Expression Technologies Limited
No active corporate controller recorded.

Latest accounts

Financial period: 1 Nov 2023 to 31 Oct 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
£717,811
Employees
18

Company events

Reference milestones and recent Companies House filing stream events.

8 events
31 Jul
2027

Accounts due

Accounts Due

Next accounts due date

02 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

07 Apr
2026

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzUxNDc2Mzk1OGFkaXF6a2N4

Published 07 Apr 2026 14:08

16 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Oct
2025

Accounts filed

Accounts

Last accounts made up date

20 Feb
2025

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQ1NTc4OTA1N2FkaXF6a2N4

Published 20 Feb 2025 06:31

01 Oct
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzNzk2Mzc2NmFkaXF6a2N4

Published 01 Oct 2024 12:54

12 Jul
2006

Incorporated

Inception

Company registered at Companies House

Public funding

8 awards
First funded
2014
Funded years
2014, 2016, 2018, 2020, 2021, 2022, 2023
Age at first award
7 years

Projects

2023 Small Business Research Initiative Lead participant

CCHFv vaccine for LMICs - transition from preclinical to clinical studies

1 Dec 2023 to 31 Mar 2026

Awarded
£1,415,760
Total cost £1,415,760

Crimean Congo Haemorrhagic Fever virus (CCHFv) is endemic in \>30 countries, almost all Low Middle Income Countries (LMICs) in Africa, the Balkans, Middle East and Asia with an estimated 3 billion people at risk. The expanding geographic range of the tick host along with trade in infected but asymptomatic livestock is fuelling the spread of CCHFv. Virus o...

2022 Small Business Research Initiative Lead participant

Development of a subunit vaccine against CCHF virus for use in low-middle income countries; completion of pre-clinical studies

1 Apr 2022 to 31 Mar 2023

Awarded
£377,408
Total cost £377,408

Crimean Congo Haemorrhagic Fever virus (CCHFv) is the most widespread tick-borne viral disease affecting people. It is endemic in \>30 countries, almost all of which are LMICs in Africa, the Balkans, Middle East and Central Asia with an estimated 3 billion people at risk. The expanding geographic range of the tick along with trade in infected but asymptom...

2021 Collaborative R&D Lead participant

COVID 19: a rapidly scaleable SARS-CoV-2 vaccine in insect cells

1 Dec 2021 to 31 Jan 2022

Awarded
£10,000
Total cost £10,000

The best validated approach to protect individuals against coronaviruses such as COVID-19 is to target the spike protein that surrounds the particle and which plays a key role in cellular attachment and virus cell entry. One of the safest ways to make spike protein for use in a vaccine is to use a production system based on a virus that can only grow in i...

2020 Collaborative R&D Lead participant

Covid-19: a rapidly scalable SARS-Cov-2 vaccine platform based on recombinant spoke protein manufactured in insect cells using flashBAC to maximise yield and quality

1 Aug 2020 to 31 Jan 2022

Awarded
£545,415
Total cost £681,769

The best validated approach to protect individuals against coronaviruses such as COVID-19 is to target the spike protein that surrounds the particle and which plays a key role in cellular attachment and virus cell entry. One of the safest ways to make spike protein for use in a vaccine is to use a production system based on a virus that can only grow in i...

2018 Small Business Research Initiative Lead participant

Development of an economically viable CCHF virus vaccine

1 Feb 2018 to 31 Jan 2022

Awarded
£2,173,000
Total cost £2,173,000

Crimean-Congo Haemorrhagic Fever (CCHF) is a serious virus (v) disease primarily transmitted to humans by ticks. The mortality rate is up to 40% with survivors experiencing long term debilitating health problems that have socio-economic impact at all levels. Incidences of the disease are increasing, with outbreaks across much of sub-Saharan Africa, large ...

2016 Collaborative R&D Lead participant

Newton Fund - Pretransplant gene therapy of pancreatic islet tissue; towards a therapy for Diabetes type I in Mexico

1 Oct 2016 to 31 Dec 2018

Awarded
£185,025
Total cost £264,322

More than 1 million people in Mexico suffer from diabetes mellitus type 1 (DM1), in which pancreatic islet cells have been damaged so that they cannot make insulin to regulate body glucose levels. Today DM1 is the most frequent metabolic disorder affecting infants and young people in Mexico. The diabetes has to be treated with life-long, daily injections ...

2016 Small Business Research Initiative Lead participant

Development of an economically viable CCHF virus vaccine for local production

1 Sep 2016 to 31 Aug 2017

Awarded
£217,428
Total cost £217,428

Some of the deadliest diseases we know about occur in areas of the world least well equipped to deal with them. The fact that they rarely cause problems in developed countries has hampered the production of preventative vaccines. Interest in these so called neglected diseases is limited owing to the small markets involved and poorly resourced healthcare. ...

2014 GRD Proof of Concept Lead participant

A novel production system for virus-like particle vaccines

1 Apr 2014 to 30 Nov 2015

Awarded
£56,750
Total cost £94,647

One of the greatest challenges to human and animal health, particularly to young adults, is the threat of emerging infectious diseases, which can spread rapidly across countries and through unprotected populations. Many of these threats come from virus diseases, in which mutations enables a virus to spread into new animal or human populations. It is there...

Product types

Collaborative R&D GRD Proof of Concept Small Business Research Initiative